Marcy l’Étoile – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2022.
- Reported growth of +4.4% over the first nine months of the year: €2,560 million in sales, -1.9% at constant exchange rates and scope of consolidation
- In Q3, higher than expected BIOFIRE® respiratory panels demand within a context of endemicity of COVID-19
- Robust performance of BIOFIRE® non-respiratory panels, Clinical microbiology and Industrial applications over the quarter
- Guidance in the upper end of the announced ranges on August, 31st
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux performed well during the third quarter of 2022. This performance demonstrates the resilience of our syndromic offer and the relevancy of our innovative portfolio of solutions dedicated to the fight against antimicrobial resistance. We confirm our 2022 objectives, targeting now the upper end of the ranges of our August guidance.”
Read the full press release
- Filename
- PR_bioMérieux_Results_Q3_2022.pdf
- Size
- 222 KB
- Format
- application/pdf